Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway
Year: 2019
Type: article
Abstract: Significance Oncogenic mutations in the BRAF gene are found in ∼50% of melanomas and drive melanoma growth. Thus, BRAF kinase inhibitors (BRAFi), such as vemurafenib and dabrafenib, have been developed and used for the treatment of BRAF-mutant metastatic melanoma in clinic. However, the clinical benefits of BRAFi are temporary and short-lived due to the emergence of drug resistance. Although several mechanisms of acquired BRAFi resistance have been identified, the basis for acquired resistance remains unknown in over 40% of melanomas. Identifying a new mechanism of acquired resistance to BRAFi may provide new opportunities to effectively treat BRAF-mutant melanoma. In this study, we have identified Block of Proliferation 1 as a new factor the loss of which results in resistance to BRAFi.
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: bronze
Awards: Predicting and profiling long-term survival after immune checkpoint inhibition, A NOVEL DRUGGABLE GENETIC VULNERABILITY PATHWAY IN MELANOMA, G308109317, G4451222777, ANOIKIS EFFECTORS AS DRIVERS OF METASTATIC MELANOMA, Nucleoporin NUP205-driven Novel Pathway in Melanoma Tumor Growth and Metastasis, A DRUGGABLE CHROMATIN MODIFIER PATHWAY IN HCC, G5925331784, G6110971809, PERSONALIZED THERAPY FOR p16-DEFICIENT MELANOMA, G7081616792, A Novel Druggable Epigenetic Vulnerability Pathway in HCC, G8260749746, Vanderbilt Clinical Oncology Research Career Development Award
OpenAlex ID: W2917632971